syfovre, also known as pegcetacoplan, is a medicine used to treat geographic atrophy, which is the advanced form of dry age-related macular degeneration. Geographic atrophy can cause irreversible ...

Geographic atrophy is an eye condition that can severely impact a person’s vision, which can affect their routine and independence. Once a person develops geographic atrophy, it cannot be reversed and ...

Randomized trials of two FDA-approved intravitreal complement inhibitor injections showed that they slowed the progression of geographic atrophy, but failed to demonstrate functional benefits at 24 ...

WALTHAM, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced that SYFOVRE ® (pegcetacoplan injection) preserved visual function at 36 months in patients with ...

WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continuous ...

Only treatment approved for use beyond 12 months for GA, a chronic disease and leading cause of vision loss WALTHAM, Mass., Oct. 20, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: ...

—Certain imaging biomarkers and demographic factors are associated with geographic atrophy growth rate and may guide the selection of patients for the use of newer therapeutics. As the population ...

No indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis Confirmed seven total events of non-occlusive/occlusive retinal vasculitis since launch; more ...

Intravitreal complement inhibitor injections (IVCIs) for geographic atrophy appeared to be acceptable to most patients if they assumed the treatment had functional vision benefits, a cross-sectional ...

SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpoint Data presented at the Clinical Trials at the Summit Meeting In a prespecified ...